Quantitation of host cell DNA contaminate in pharmaceutical-grade plasmid DNA using competitive polymerase chain reaction and enzyme-linked immunosorbent assay

The rising interest in gene therapy for the treatment of numerous disorders necessitates the need for the large-scale production of therapeutic biopharmaceuticals that meet stringent purity standards. Residual host cell DNA in recombinant pharmaceuticals has been identified as a potential risk facto...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Human gene therapy 1998-05, Vol.9 (8), p.1173-1180
Hauptverfasser:	Lahijani, R, Duhon, M, Lusby, E, Betita, H, Marquet, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Binding, Competitive Blotting, Southern Cells, Cultured DNA - analysis DNA Restriction Enzymes DNA, Bacterial - genetics Enzyme-Linked Immunosorbent Assay Escherichia coli - genetics Genetic Therapy Humans Plasmids - genetics Polymerase Chain Reaction - methods Sensitivity and Specificity Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!